SCHOTT Pharma Achieves Robust Growth Post-IPO, Surpassing Revenue Expectations

0 comment 2 minutes read

Pioneering pharmaceutical solutions provider, SCHOTT Pharma, concludes fiscal year 2023 on a high note, exceeding revenue projections and maintaining strong profitability.

SCHOTT Pharma, a leading player in pharmaceutical drug containment solutions and delivery systems, has successfully wrapped up its fiscal year 2023 with revenues reaching EUR 899 million, marking a robust 9% growth compared to the previous fiscal year. The impressive performance comes despite temporary de-stocking in the core vials product category. The company’s EBITDA, aligning with revenue growth, reached EUR 239 million, maintaining a commendable EBITDA margin of 26.6%. Key to this success was the strategic expansion of production capacities, particularly in drug delivery systems and the establishment of new production lines for prefillable polymer syringes in Müllheim, Germany.

This expansion has proven pivotal, contributing to the noteworthy increase in the share of revenue from high-margin high-value solutions (HVS) by 9 percentage points, reaching an impressive 48%, surpassing initial expectations. Dr. Almuth Steinkühler, CFO of SCHOTT Pharma, expressed satisfaction, stating, “Our ability to fulfill growth targets post-IPO reflects our commitment to pharma trends and the burgeoning market for high-value solutions. The robust growth and profitability affirm our strategic direction and fuel our confidence in both the upcoming financial year and our mid-term objectives.”

Despite challenges like customer de-stocking affecting the core vials product category in the latter part of the financial year, the strong performance of high-value solutions has been a driving force behind SCHOTT Pharma’s remarkable overall growth.

SCHOTT Pharma’s product portfolio aligns with crucial pharmaceutical trends, including GLP-1, home-care, and mRNA applications, positioning the company to capitalize on continued growth opportunities. As of December 18, 2023, SCHOTT Pharma proudly joined the SDAX, marking its entry into the DAX family for the first time. The company is set to unveil its 2023 annual report, along with the non-financial report, on January 26, 2024.

Source: SCHOTT Pharma with additional information added by Apazone

You may also like

Leave a Comment


Subscribe to our newsletter and be the first to explore new blog posts, uncover tips, and view inspiring photos, all curated just for you.

Leave this field blank

Follow us on

About us


© 2023 All rights reserved.

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Accept All Cookies Cookies Policy